Class / Patent application number | Description | Number of patent applications / Date published |
435600140 | Detecting cancer | 82 |
20110124004 | UTILITY OF HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN IN DIAGNOSIS AND TREATMENT OF CANCER - HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells. | 05-26-2011 |
20110124005 | REAGENT FOR DETECTING ABNORMAL CELL IN CERVIX OF UTERUS, AND METHOD FOR DETECTING ABNORMAL CELL IN CERVIX OF UTERUS BY USING SAME - Disclosed is a reagent for detecting an abnormal cell in the cervix of uterus, which can detect an abnormal cell contained in a biological sample that contains cells collected from the cervix of uterus. The reagent comprises a dye represented by general formula (I). | 05-26-2011 |
20110129844 | Use of Activating Transcription Factor-2 (ATF2) for Detecting Skin Cancer - The present invention is based on the discovery of the tumor suppressor role of activating transcription factor 2 (ATF2) in non-melanoma skin cancer development. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having skin cancer. Also provided are methods of treating skin cancer in a subject, characterizing skin cancer in a subject, and identifying agents useful for treating skin cancer in a subject. | 06-02-2011 |
20110136129 | ASSESSING ATYPICAL HYPERPLASIA PATIENTS FOR THE RISK OF DEVELOPING BREAST CANCER - This document provides methods and materials involved in assessing the risk of developing breast cancer in patients with atypical hyperplasia. For example, methods and materials for using the level of Ki67 expression (e.g., percent Ki67 | 06-09-2011 |
20110143360 | CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT - The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494. | 06-16-2011 |
20110143361 | PREDICTIVE VALUE OF NUCLEAR EXCISION REPAIR GENES FOR CANCER SURVIVAL - Patients who have their cancer surgically removed are at risk for recurrence, even though currently free of disease. Lung cancer patients with higher activity of a nuclear excision repair gene called ERCC1 were at a lower risk for recurrence than patients with lower activity of ERCC1. Hence, it is possible to predict which patients are at a higher risk for recurrence after resection. This information can be used to design treatment strategies for patients determined to be at a higher risk for recurrence. Additionally, patients who are lower risk for recurrence can be saved the morbidity of further treatment. | 06-16-2011 |
20110151472 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 06-23-2011 |
20110159508 | GFATS as Modifiers of the P53 Pathway and Methods of Use - Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided. | 06-30-2011 |
20110159509 | USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts. | 06-30-2011 |
20110159510 | USE OF METHYLATED OR UNMETHYLATED LINE-1 DNA AS A CANCER MARKER - The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment. | 06-30-2011 |
20110165582 | MOLECULAR METHOD FOR DIAGNOSIS OF COLON CANCER - Methods for diagnosing or detecting cancerous colon tissue. A panel of 17 specific marker genes are provided. The overexpression of some of these marker genes compared to their expression in normal human colon tissue and the underexpression of the rest of these marker genes are indicative of cancerous colon tissue. By using these 17 marker genes as a diagnostic tool, smaller tissue samples, such as those obtained by core needle biopsies, from patient stool samples, or from blood samples can be used. | 07-07-2011 |
20110195421 | METHODS OF IDENTIFYING BIOMARKERS FOR CANCER - Methods of Identifying Biomarkers for Cancer. According to at least one embodiment of a method of identifying diagnostic markers of cancer of the present disclosure, the method comprises the steps of contacting a body fluid of a diseased subject having a cancer with a stabilizing agent capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker, analyzing the stabilized body fluid to determine at last one property of the diagnostic marker to create a cancer profile, comparing the cancer profile with a control profile of a healthy subject not having the cancer, wherein the control profile is created in a like manner to the cancer profile, and generating a cancer identifier panel from the compared cancer profile, wherein the cancer identifier panel contains at least one cancer diagnostic marker indicative of the cancer. | 08-11-2011 |
20110195422 | METHODS FOR DETERMINING THE EFFICIENCY OF A THERAPEUTIC - Methods for determining the efficiency of a therapeutic. In at least one embodiment of a method of determining the efficacy of a therapeutic compound, the method comprises the steps of treating a subject having a disease state with an effective amount of therapeutic compound, harvesting at least one cell from the subject following a treatment with the therapeutic compound, bringing the at least one cell into contact with a stabilizing compound capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker for the disease state, analyzing the at least one stabilized cell for the at least one diagnostic marker, creating a marker profile from at least one result determined from analyzing the at least one stabilized cell, and comparing the marker profile with at least one previous marker profile to determine efficacy of the therapeutic compound on the disease state. | 08-11-2011 |
20110201012 | METHODS AND COMPOSITIONS FOR DIAGNOSING EPITHELIAL CELL CANCER - Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx, the overexpression of a nucleic acid of KS1/4, or the overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx in non-primary tissue being correlated with metastases of epithelial cancers. | 08-18-2011 |
20110212456 | K-ras and B-raf mutations and anti-EGFr antibody therapy - The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to B-raf mutations, to polynucleotides encoding mutant B-raf polypeptides, to vectors containing those polynucleotides, and to methods of identifying B-raf mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors. | 09-01-2011 |
20110217717 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR LUNG DISORDERS USING GENE EXPRESSION PROFILES FROM NOSE EPITHELIAL CELLS - The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer. | 09-08-2011 |
20110223607 | CIRCULATING MICRORNA AS A MARKER FOR HEPATOCELLULAR CARCINOMA - Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids. | 09-15-2011 |
20110236903 | MATERIALS AND METHODS FOR DETERMINING DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER - Materials and Methods related to diagnosing and/or determining prognosis of prostate cancer. | 09-29-2011 |
20110244473 | Methods and materials for observing apoptosis - The invention provides methods and materials for observing protein fragments generated during apoptosis in order to observe this process in mammalian cells. Embodiments of the invention can be used for example to observe apoptosis in order to examine the sensitivity of a mammalian cancer cell to apoptosis inducing agents. | 10-06-2011 |
20110250608 | USE OF ULTRACONSERVED RNA IN DETECTION AND TREATMENT OF CANCER - A method of analyzing a biological specimen to detect cancer in a subject, involving determining an ultraconserved RNA in the specimen and comparing the expression level to a control. The ultraconseved RNA may be uc.338 and may be used to detect hepatocellular cancer. Transcript RNA encoding ultraconserved RNA may also be used to detect cancer. Anti-cancer compositions and tumor-suppressing agents for treating cancer are also provided. | 10-13-2011 |
20110256546 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER RESISTANT TO ANAPLASTIC LYMPHOMA KINASE (ALK) KINASE INHIBITORS - Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants. | 10-20-2011 |
20110256547 | MicroRNAa (miRNA) AS BIOMARKERS FOR DIAGNOSING DIFFERENT GRADES OF GLIOMAS AND PATHWAYS OF GLIOMA PROGRESSION - This invention relates to a method for detecting, (i) malignant astrocytoma from normal brain tissue (ii) glioblastoma and anaplastic astrocytoma (iii) primary glioblastoma and secondary glioblastoma (iv) progressive pathway and denovo pathway comprises determining the level of expression of miRNAs listed in table 2, 3, 4, 5, wherein a higher or lower level of expression of miRNAs in the test sample as compared to the control sample differentiates and kit for characterizing a) malignant astrocytoma from normal brain tissue cell comprising reagent capable of specifically detecting the level of expression of the genes of miRNAs and instructions for using said kit for characterizing malignant astrocyoma from normal brain tissue cells b) glioblastoma from anaplastic astrocytoma comprising reagent capable of specifically detecting the level of expression of the genes of miRNAs and instructions for using said kit for characterizing glioblastoma from anaplastic astrocyoma c) primary glioblastoma from secondary glioblastoma comprising reagent capable of specifically detecting the level of expression of the genes of miRNAs and instructions for using said kit for characterizing primary glioblastoma from secondary glioldastoma, d) progressive pathway from denovo pathway comprising reagent capable of specifically detecting the level of expression of the genes of miRNAs and instructions for using said kit for characterizing progressive pathway from denovo pathway. | 10-20-2011 |
20110269142 | Clinical Method for Individualized Epithelial Cancer Screening Involving ERCC5 and IGF2R Genetic Testing and Gene-Environment Interactions - A system for determining individualized risk of developing aerodigestive cancers or cancers of the liver is described. Methods and compositions for assessing ERCC5 and/or IGF2R genetic variation and expression and their effects in view of certain environmental exposures in determining the risk of an individual for developing one or more epithelial cancers are provided. The system includes a kit used to collect a DNA sample from an individual and data related to the individual's medical and occupational history, use of tobacco and alcohol products as well as the individual's environment. An algorithm may be applied to transform the DNA sample and data into an individualized risk score, accounting for inter-individual variation in genetic profile and environmental/lifestyle exposures. The risk score may be indicative of the individual's risk of having or developing epithelial cancer, and the cancers prognosis. The risk score may be distributed to one or more of the individual, physician and other personnel. Test results and risk score have novel clinical utilities; diagnosis, prognosis, and treatment programs and activities may be facilitated by one or more of the kit and the risk score. | 11-03-2011 |
20110275089 | Methods for predicting survival in metastatic melanoma patients - Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients. | 11-10-2011 |
20110281277 | COMPOSITION, KIT, AND METHOD FOR DIAGNOSING COLORECTAL CANCER OR OVARIAN CANCER - The present invention relates to a composition for diagnosing colorectal cancer or ovarian cancer, comprising gene markers for quickly and correctly diagnosing colorectal cancer or ovarian cancer, and more particularly, to a composition for diagnosing colorectal cancer or ovarian cancer, comprising an agent measuring mRNA or protein levels of two or more genes selected from the group consisting of CK7 (cytokeratin 7), CK20 (cytokeratin 20), CDX2 (caudal type homeobox transcription factor 2), and MUC2 (mucin 2), a diagnostic kit comprising the composition, and a diagnostic method. | 11-17-2011 |
20110294134 | METHODS AND KITS FOR DETERMINING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER - Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed. | 12-01-2011 |
20110300550 | METHOD FOR DETECTING NUCLEIC ACID IN BIOLOGICAL SAMPLE - The present invention is to provide a method capable of efficiently and readily detecting a nucleic acid from a biological sample such as feces. | 12-08-2011 |
20110300551 | METHOD OF PREDICTING CLINICAL OUTCOMES FOR MELANOMA PATIENTS USING CIRCULATING MELANOMA CELLS IN BLOOD - The present invention provides an automated method for capturing and detecting circulating melanoma cells (CMC's) in the blood of patients with melanoma. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. | 12-08-2011 |
20110306055 | Method for Detecting Metastasis of GI Cancer - The present invention provides a novel method for diagnosing, monitoring, prognosing and staging Lymph Node (LN) status in colorectal cancer (CRC) that is more sensitive and accurate than conventional detection technologies such as histopathology. The Guanylyl Cyclase C (GCC) gene is specifically expressed in apical epithelial cells of the GI tract from the duodenum to the rectum and the detection of GCC mRNA in LNs is indicative of the presence of metastases. Quantitative RT-PCR (RT-qPCR) detection of GCC mRNA to identify the presence of colorectal cancer (CRC) cells in LNs has the potential to aid in CRC staging. When used in combination with glucuronidase B (GUSB), accurate quantification of GCC can be achieved with less than a 2-fold variation between intact and highly degraded RNA specimens. The invention also relates to a newly designed GCC/GUSB assay that uses relative quantification having improved prognostic value for time to recurrence and relapse-free survival in Stage I or II colon cancer patients. The GCC/GUSB assay also improves the statistical power of prognosis stratification for relative risk of recurrence and relapse-free survival. | 12-15-2011 |
20120028264 | METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER - Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein. | 02-02-2012 |
20120040366 | COMPOSITIONS, METHODS AND USES FOR DISEASE DIAGNOSIS - Embodiments of the present invention generally related to methods and compositions for diagnosing or predicting a genetic disorder. In certain embodiments, the methods may include use of rapid and inexpensive assay systems. Other embodiments concern novel mutation specific peptides associated with BRCA1 or BRCA2. In yet other embodiments, haploid cells are used to diagnose a genetic disorder in a subject. | 02-16-2012 |
20120045771 | METHOD FOR ANALYSIS OF NUCLEIC ACID POPULATIONS - The invention relates to a method for isolation of target molecules from a nucleic acid population. | 02-23-2012 |
20120077202 | Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 03-29-2012 |
20120107827 | PSMCs As Modifiers of the RB Pathway and Methods of Use - Human PSMC genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of PSMC are provided. | 05-03-2012 |
20120122112 | ANTIBODIES AS A CANCER DIAGNOSTIC - Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2. | 05-17-2012 |
20120142013 | NUCLEIC ACID APTAMER CAPABLE OF BINDING SPECIFICALLY TO PANCREATIC CANCER CELLS OR TISSUES AND USE THEREOF - The present invention relates to a nucleic acid aptamer which can specifically recognize and bind to pancreatic cancer cells or tissues. The nucleic acid aptamer can bind specifically only to pancreatic cancer cells or tissues without binding to normal pancreatic cancer tissue, and thus can be effectively used as a composition for diagnosing and treating pancreatic cancer. In addition, the nucleic acid aptamer can detect not only the terminal pancreatic cancer cell line Capan-1, but also the early pancreatic cancer cell line Panc-1, and thus can be used for early diagnosis of pancreatic cancer, thereby contributing to increasing the survival rate of pancreatic cancer patients. | 06-07-2012 |
20120171691 | METHOD FOR MONITORING THE BISULFITE-MEDIATED CONVERSION OF DNA - The present invention relates to a method for monitoring the progression of the bisulfite-mediated conversion of DNA during DNA methylation analysis. The method is based on the reaction of the enzyme uracil-DNA-glycosylase (UNG) with at least one labeled DNA reporter molecule, the reporter molecule comprising at least one unmethylated cytosine residue in its sequence. After bisulfite-mediated conversion of unmethylated cytosine residues in uridin residues UNG removes the uracil bases from the DNA backbone, thus making it susceptible to heat-induced hydrolytic cleavage. Finally, the labels released from the DNA reporter molecule during this fragmentation process are detected. | 07-05-2012 |
20120309015 | METHODS AND COMPOSITIONS FOR DETECTING ENDOMETRIAL OR OVARIAN CANCER - Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided. | 12-06-2012 |
20130022987 | Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery - The invention relates to the discovery and use of novel antigens/autoantigens, polyclonal and monoclonal antibodies/autoantibodies thereto, and in particular methods of using the antigens/autoantigens and antibodies/autoantibodies in the diagnostic, prognostic, staging and therapeutic regimens for the control of colorectal cancer. | 01-24-2013 |
20130045485 | METHOD FOR ANALYSIS OF CELLULAR DNA CONTENT - Disclosed is a fast and simple method for quantification of nucleic acid of biological cells as 2-step protocol. In the first step cells are treated with an acidic solution containing a non-ionic detergent and a fluorescent DNA specific label. In the second step the sample may be neutralised. Determining of the content of nucleic can be performed by fluorescence microscopy. The method may also be used for obtaining information of cell cycle analysis, ploidy determination, measurements of nucleotide incorporation and assays for proliferation, health, stress level, apoptosis, necrosis, or other state of conditions of cells. The invention also relates to a kit of parts comprising an acidic agent, a detergent, a labelling agent and optionally a neutralization agent. | 02-21-2013 |
20130189704 | NUCLEIC ACID DETECTION ASSAY - This invention is directed, inter alia, to methods and kits for rapid, easy and cost-effective methods of breast cancer prediction and diagnosis in inter alia, blood samples. | 07-25-2013 |
20130196335 | PROGNOSTIC METHODS, COMPOSITIONS AND KITS FOR PREDICTION OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) RELAPSE - The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL. | 08-01-2013 |
20130224755 | METHOD FOR DETECTING DNA ADDUCTS IN SALIVA - A method of detecting DNA adducts in saliva is disclosed herein. The method comprises the following steps: providing a salivary DNA; adding at least one isotope-labeled internal standard and a plurality of enzymes into the salivary DNA to hydrolyze the salivary DNA into a plurality of nucleosides; extracting the plurality of nucleosides by using a solid-phase extraction column; and detecting and quantifying at least one DNA adduct in the plurality of extracted nucleosides by utilizing a stable isotope dilution nano-flow liquid chromatography-nanospray ionization tandem mass spectrometry (LC-NSI/MS/MS). | 08-29-2013 |
20130280729 | CANCERATION INFORMATION PROVIDING METHOD AND CANCERATION INFORMATION PROVIDING DEVICE - Provided is a canceration information providing method capable of presenting the information related to canceration of the cells with high reliability. A cell in which the amount of DNA is greater than or equal to the amount of DNA of the normal cell in the S period is extracted from a cell group of V | 10-24-2013 |
20130280730 | CANCERATION INFORMATION PROVIDING METHOD AND CANCERATION INFORMATION PROVIDING DEVICE - Provided is a canceration information providing method capable of presenting information related to canceration of cells with high reliability. A cell in which an amount of DNA is greater than or equal to an amount of DNA of a normal cell in a S period is extracted from a cell group of V | 10-24-2013 |
20130295580 | ORAL CANCER POINT OF CARE DIAGNOSTICS - A point of care diagnostic test, device and disposables for determining a patient risk for oral cancer in the same visit that a sample is collected. | 11-07-2013 |
20130295581 | Methods and Compositions for the Treatment and Diagnosis of Breast Cancer - The invention provides methods, compositions and kits relating to the diagnosis, prognosis and treatment of breast cancer. | 11-07-2013 |
20130309685 | METHOD FOR TARGET BASED CANCER CLASSIFICATION, TREATMENT, AND DRUG DEVELOPMENT - A method of classifying a cancerous tumor is described and comprises the steps of: screening a set of targetable events within a tumor, determining a profile for tumor, and classifying the tumor based on the variant profile of the tumor. More specifically, the tumor is defined and classified based on targetable events; histology and disease stage are not considered. The method will result in greater numbers of samples for clinical studies and better, more accurate combinatorial approaches for treatment. This method overcomes the biases of traditional cancer classification schemes, and advances personalized medicine in solid tumor cancers. | 11-21-2013 |
20140011207 | PSA BINDING APTAMER AND METHOD FOR DIAGNOSIS OF PROSTATE CANCER - The present invention provides an aptamer that binds to prostate-specific antigen (PSA), the aptamer including: a preceding region having a random polynucleotide sequence consisting of from 1 to 10 nucleotides; a first region, at a 3′ end of the preceding region, consisting of nnnnCT wherein each n is independently selected from A, T, G and C; a second region consisting of nnCTTT wherein each n is independently selected from A, T, G and C, and at least one part of the second region is complementary to the first region; and a third region positioned between the first region and the second region and consisting of a random polynucleotide sequence having from 3 to 30 nucleotides. | 01-09-2014 |
20140030727 | LOSS OF 5-HYDROXYMETHYLCYTOSINE AS A BIOMARKER FOR CANCER - Methods for detecting or diagnosing cancer in a subject are provided herein. Such methods may include, but are not limited to, measuring a test level of 5hmC in a biological sample from the subject; and determining that the subject has a malignant cancer when the test level of 5hmC is lower than that of a control level of 5hmC. Such methods may further include a step of measuring a test level of Ki67 in the biological sample and determining that the subject has a malignant cancer when the test level of Ki67 is higher than that of a control level of Ki67. | 01-30-2014 |
20140030728 | METHOD AND APPARATUS FOR ANALYZING CELLS - A method of analyzing cells, the method comprising: measuring a number of cells which are nuclear stained, in a to-be-determined tissue, and acquiring a histogram showing a fluorescence intensity based on a result of the measurement; analyzing the histogram, and acquiring data of predetermined parameters; comparing the data of the parameters with first thresholds predetermined for the parameters, to perform a first cancer determination for each of the parameters on the to-be-determined tissue; performing a scoring process for each of the parameters, on a result of the first cancer determination for each of the parameters, to calculate scores of the parameters; and combining the scores of the parameters with one another, thereby performing a second cancer determination on the to-be-determined tissue. | 01-30-2014 |
20140030729 | DETECTION OF CIRCULATING TUMOR CELLS USING IMAGING FLOW CYTOMETRY - An automated identification of the types of white blood cells in a blood sample facilitates the manual identification of cancerous or other abnormal blood cells in the sample. Classifiers are predetermined for each type of white blood cell and subsequently used to automatically process images of cells in a sample stained with a nuclear dye or stain. The classifiers each comprise a linear weighted combination of morphometric and photometric features previously selected for white blood cells that were identified using monoclonal antibody stains. Red blood cells and excess fluid are removed from a sample being processed upstream of an imaging region of the imaging system. A plurality of different types of images are produced for each cell by the imaging system enabling automated identification of the white blood cells. Images of any cells not thus identified are manually reviewed to detect cancerous or abnormal cells. | 01-30-2014 |
20140093886 | Method of diagnosing cancer using a nucleolin specific aptamer - Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided. | 04-03-2014 |
20140178890 | AGENT FOR IMPROVING CANCER CELL ADHESIVENESS - A polymer comprising a constitutional unit represented by the following formula (1) is useful because when the polymer is applied to a surface of a cancer cell enrichment filter, adhesiveness of cancer cells to the filter surface can be improved so that an enrichment ratio of the cancer cells can be improved. In the formula (1), R | 06-26-2014 |
20140199702 | CANCERATION INFORMATION PROVIDING METHOD AND CANCERATION INFORMATION PROVIDING DEVICE - There is provided a canceration information providing method which can detect the possibility of cancer in the initial stage with high accuracy. The canceration information providing method for providing information pertaining to canceration of cells includes: acquiring measurement data including first data pertaining to size of a cell nucleus and second data pertaining to size of a cytoplasm for each cell contained in a measurement sample which includes cells collected from epithelial tissue; extracting the measurement data of cells to be analyzed, which are at least some of the cells located toward the basal membrane side of the cells existing in the surface layer in the epithelial tissue, from the measurement data of a plurality of cells in the measurement sample based on the first data and the second data acquired for each cell; and analyzing the extracted measurement data and outputting the information pertaining to the canceration of cells. | 07-17-2014 |
20140206011 | METHODS AND COMPOSITIONS OF DIAGNOSING AND TREATING FUSOBACTERIUM NUCLEATUM RELATED DISORDERS - A method of identifying a subject with increased risk of colorectal cancer includes obtaining a biological sample from the subject, measuring the level of | 07-24-2014 |
20140295450 | CELL ANALYZING METHOD AND CELL ANALYZER - The present invention provides a method for analyzing a cell. The method comprises steps of: regulating a temperature of a medium to a predetermined degree, wherein the cell is preserved in the medium; and obtaining an optical information by irradiating light on the cell. | 10-02-2014 |
20140302514 | CANCER SCREENING BY DETECTION OF ULTRASTRUCTURAL AND MOLECULAR MARKERS - The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject. | 10-09-2014 |
20140329249 | SELECTIVE RELEASE OF SUB-GROUP OF BIOLOGICAL UNITS - A method of individually releasing from an entity one or more members of a sub-group of biological units included in a heterogeneous group of biological units is provided. The method includes binding the group of biological units including the sub-group of biological units to the entity via a linker. Following binding, the location of the one or more members on the entity is determined. Once the location is determined, a localized physical pulse is applied to the one or more members. The localized physical pulse individually releases the one or more members from the entity by dissociating the linker. | 11-06-2014 |
20140335533 | Method of Preparing Quality Control Material for FFPE - This specification relates to Formalin-fixed embedded quality control material for use for validation, verification, and to run controls for molecular assays. The quality control material can be used for a variety of tissues and for a variety of molecular assays. The quality control material can be used in commercial labs for validation and limit-of-detection analyses. | 11-13-2014 |
20150010912 | METHODS OF DETECTING TUMOR CELLS - In one aspect, methods of detecting tumor cells are described herein. In some embodiments, a method of detecting tumor cells comprises providing a device, the device comprising a substrate surface and a plurality of first aptamer probes attached to the substrate surface. The method further comprises contacting a plurality of cells with the plurality of first aptamer probes attached to the substrate surface; adhering one or more of the plurality of cells to the substrate surface; and measuring a non-uniformity parameter, a Hausdorff distance, a change in the number of pseudopods, and/or a shape of at least one adhered cell. In some cases, the method further comprises using the non-uniformity parameter, Hausdorff distance, change in the number of pseudopods, and/or shape of the adhered cell to identify the adhered cell as a tumor cell or a non-tumor cell. | 01-08-2015 |
20150010913 | MONOCLONAL ANTIBODY FOR DETECTING EXOSOMES - A monoclonal antibody for detecting or capturing an exosome, selected from the group consisting of a monoclonal antibody or antibody fragments thereof that recognize amino acid numbers 113 to 195 of the amino acid sequence as shown in SEQ ID NO: 1, a monoclonal antibody or antibody fragments thereof that recognize amino acid numbers 104 to 202 of the amino acid sequence as shown in SEQ ID NO: 2, a monoclonal antibody or antibody fragments thereof that recognize amino acid numbers 36 to 54 of the amino acid sequence as shown in SEQ ID NO: 3, and a monoclonal antibody or antibody fragments thereof that recognize amino acid numbers 113 to 201 of the amino acid sequence as shown in SEQ ID NO: 3, each capable of detecting or capturing an exosome. The monoclonal antibody for detecting an exosome of the present invention is capable of detecting CD9, CD63 or CD81 on the exosome in a living body with an excellent sensitivity and specificity. | 01-08-2015 |
20150010914 | BIOMARKERS FOR GASTRIC CANCER AND USES THEREOF - The present invention provides biological markers associated with gastric cancer. In particular, the present invention provides a method of diagnosing gastric cancer (GC) in a subject, the method including: measuring an expression level of one or more proteins in the subject, wherein the one or more proteins are selected from the group consisting of vitamin D binding protein (VDBP), clusterin, insulin like growth factor binding protein complex acid labile subunit (IGFALS), and afamin; comparing the expression level of the or each protein in the subject to a reference expression level for the or each protein; and diagnosing GC in the subject on the basis of the comparison. On the basis of the identification of biological markers associated with gastric cancer, the present invention also provides a method of determining if a subject is susceptible to developing gastric cancer, a method of assessing progression of gastric cancer in a subject, a method for screening a candidate therapeutic agent useful for treating gastric cancer in a subject, and a kit for diagnosing gastric cancer in a subject. | 01-08-2015 |
20150037805 | DOUBLE-STRANDED NUCLEIC ACID, USE AND KIT THEREOF IN RIBONUCLEASE DETECTION - Provided are a double-stranded nucleic acid and use thereof in ribonuclease detection, and a ribonuclease detection method and use thereof in tumor detection and/or diagnosis. Specifically, a double-stranded nucleic acid substrate comprises at least one ribonuclease sensitive site. The activity and content of the ribonuclease in a sample are detected by analyzing the degradation of the double-stranded nucleic acid substrate by the ribonuclease. Also provided are a ribonuclease detection kit and a tumor detection kit. | 02-05-2015 |
20150086996 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR - The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3′ cap. In some embodiments, the 3′ cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5′-end of the aptamer and the moiety is attached the 5′ end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore. | 03-26-2015 |
20150299805 | NUCLEIC ACID DETECTION ASSAY - This invention is directed, inter alia, to methods and kits for rapid, easy and cost-effective methods of breast cancer prediction and diagnosis in inter alia, blood samples. | 10-22-2015 |
20150323539 | BLOOD MARKERS FOR LUNG CANCER PREDISPOSITION - The invention provides a method for detection of lung cancer, or predisposition to lung cancer, in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of lung cancer, or predisposition to lung cancer. The method can be adapted for quantitatively monitoring the efficacy of treatment of lung cancer in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitrotyrosine oxidative activity (protein nitrosylation in leukocytes). This unexpected discovery of markers of systemic genotoxicity that can be tested using circulating leukocytes enables detection of lung cancer, or predisposition to lung cancer, with a relatively simple and minimally invasive assay using peripheral blood. | 11-12-2015 |
20160011198 | DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC) | 01-14-2016 |
20160040248 | METHOD TO IMPROVE EXPRESSION AND OTHER BIOLOGICAL ANALYSIS - A method to verify single data points by substituting multiple data points that predict the original value measured is described. This is applied to determining gene expression levels. | 02-11-2016 |
20160054326 | RARE CELL CONCENTRATION - A ratio of rare cells to non-rare cells in a blood sample suspected of containing rare cells and non-rare cells is enhanced. A treated blood sample is prepared by providing in combination the blood sample, a platelet deactivation agent, a fibrin-formation-arresting agent and fibrin in an amount sufficient to cause a predetermined level of agglutination of the rare cells. The treated blood sample is then contacted with a porous matrix such that agglutinated rare cells are preferentially retained on the porous matrix. The rare cells may then be identified. | 02-25-2016 |
20160061840 | OVARIAN CANCER-SPECIFIC APTAMERS AND APPLICATIONS THEREOF - The present invention provides ovarian cancer-specific aptamers, which are selected in vitro using SELEX and a microfluidic chip system. The aptamers can also bind to different histologically-classified ovarian cancer cells with high affinity accordingly. Therefore, the aptamers of the present invention and the applications thereof can not only be used in detection of ovarian cancer cells but also be applied in recognition of different histologically-classified ovarian cancer cells. | 03-03-2016 |
20160091428 | METHOD FOR DETERMINING ABNORMALITY IN PARTICLE ANALYZER AND PARTICLE ANALYZER - Disclosed is a method for determining abnormality in a particle analyzer. The method includes: staining first control particles but not staining second control particles which emit fluorescence; irradiating with light the first control particles and the second control particles flowing in a flow cell, and detecting fluorescence from the first control particles and the second control particles; obtaining a first management value indicating a detection result of the fluorescence emitted from the first control particles and a second management value indicating a detection result of the fluorescence emitted from the second control particles; and determining abnormality in the staining step, based on a value calculated from the first management value and the second management value or a ratio between the first management value and the second management value. | 03-31-2016 |
20160097101 | APTAMER SPECIFIC TO COLORECTAL CANCER CELL AND APPLICATION THEREOF - The present invention provides an aptamer specific to colorectal cancer cells and comprises a nucleotide sequence selected from the group consisting of Seq ID: NO. 1 to Seq ID: NO. 14. The aptamer of the present invention specific to colorectal cancer cell may be applied in colorectal cancer detection and provide a detection method having non-invasive, fast and convenient properties. | 04-07-2016 |
20160109468 | ASSOCIATING SOMATIC GENE MUTATIONS IN GLYCOPHORIN A WITH COMPLEX MULTIFACTORIAL DISEASES - In the detection of a complex multi-factorial disease, an MN blood group typing is performed on a first blood sample of a subject to be tested for a complex multifactorial disease, and on a second blood sample of a control subject having known phenotypes. Erythrocytes from the samples are isovolumetrically sphered, and M alleles and N alleles expressed on surfaces of erythrocyte cells of the first and second blood samples are labeled by contacting the blood samples with anti-M antibodies and anti-N antibodies associated with a marker. Labeled M alleles and labeled N alleles in the first and second blood samples are detected and quantified using the marker, in order to determine an incidence of somatic mutations in Glycophorin A of the patient. The incidence is compared with data pertaining to patients with a known complex multi-factorial disease, to diagnose the patient. | 04-21-2016 |
20160130653 | POLYNUCLEOTIDE PROBE, METHOD FOR DETECTING A TARGET NUCLEIC ACID BY USING THE SAME AND KIT COMPRISING THE SAME - The present invention provides a method for detecting a target nucleic acid that comprises a step of providing a sample; contacting the sample with a polynucleotide probe comprising a first sequence and a second sequence complementary to the target nucleic acid; and adding a nuclease for cleaving the second sequence of the polynucleotide probe. The present invention further provides a polynucleotide probe for detecting a target nucleic acid that comprises a first sequence and a second sequence complementary to the target nucleic acid. Moreover, the present invention provides a kit for detecting a target nucleic acid. | 05-12-2016 |
20160188825 | SYSTEM AND METHOD FOR CYTOPATHOLOGICAL AND GENETIC DATA BASED TREATMENT PROTOCOL IDENTIFICATION AND TRACKING - A method of assessing a target including collecting patient data, identifying a target in an image dataset, preparing a pathway plan to arrive at the target, inserting a medical instrument and following the pathway plan to arrive at the target from an opening, extracting a first biopsy sample from the target, performing a cytopathological examination on the biopsy sample, collecting genetic information from the biopsy sample, and presenting one or more treatment options based on a correlation of the patient data, the cytological examination, and the genetic information of the first biopsy sample, and their comparison to the patient data, cytological examination and genetic information of previously acquired biopsy samples. The method may further include acquiring a second biopsy sample. | 06-30-2016 |
20180024141 | METHOD FOR THE ENRICHMENT OF CIRCULATING TUMOR DNA | 01-25-2018 |
20190144951 | METHODS AND COMPOSITIONS FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT | 05-16-2019 |
20190145962 | PEPTIDE FOR INHIBITING BINDING OF AMYLOSPHEROIDS (ASPD), AND EVALUATION AND SCREENING METHOD | 05-16-2019 |
20190147975 | SF3B1 SUPPRESSION AS A THERAPY FOR TUMORS HARBORING SF3B1 COPY LOSS | 05-16-2019 |
20220136062 | METHOD FOR PREDICTING CANCER RISK VALUE BASED ON MULTI-OMICS AND MULTIDIMENSIONAL PLASMA FEATURES AND ARTIFICIAL INTELLIGENCE - The present application relates to the field the field of bioinformatics. Specifically, the present application relates to a method, system, electronic device and computer-readable medium for predicting the source of a sample to be tested based on multi-omics and multidimensional plasma features and artificial intelligence. | 05-05-2022 |
20220136066 | METHOD TO DIAGNOSE A CMMRD - The present invention relates to the diagnostic of CMMRD. In the present work, the inventors aimed to develop a test that could drastically simplify and improve the diagnosis of CMMRD based on DNA sequence analysis of primary blood cells (PBCs) from patients. Using massive parallel sequencing, they explored the possibility that MSI, the main genomic and functional consequence of constitutive MMR-deficiency, was likely to occur in CMMRD PBCs well before any transformation. Thus the present invention relates to a method of diagnosing a CMMRD cancer or a MSI leukemia/lymphoma in a patient in need thereof. | 05-05-2022 |